Home > Newsletters > FDAnews Drug Daily Bulletin > Afinitor Gets Expanded Indication as Pediatric Brain Tumor Treatment
FDAnews Drug Daily Bulletin
Sept. 13, 2012 | Vol. 9 No. 180
Afinitor Gets Expanded Indication as Pediatric Brain Tumor Treatment
The FDA has approved Novartis’ Afinitor to treat a rare brain tumor called subependymal giant cell astrocytoma (SEGA) in children, expanding its indication for the condition. In clearing Afinitor Disperz (everolimus tablets oral suspension), the agency also advanced the first approved drug formulated for children with rare brain tumors, the FDA said.
Washington Drug Letter
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.